SCYNEXIS (SCYX) 10-Q 9 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 01, 2022
Cover [Abstract]
Entity Registrant Name	SCYNEXIS, Inc.
Trading Symbol	SCYX
Entity Central Index Key	0001178253
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		32,656,992
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity File Number	001-36365
Entity Tax Identification Number	56-2181648
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1 Evertrust Plaza
Entity Address, Address Line Two	13th Floor
Entity Address, City or Town	Jersey City
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07302-6548
City Area Code	201
Local Phone Number	884-5485
Document Quarterly Report	true
Document Transition Report	false
Title of Each Class	Common Stock, par value $0.001 per share
Name of Each Exchange on Which Registered	NASDAQ

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 68,620	$ 104,484
Short-term investments	27,470
Prepaid expenses and other current assets	4,141	3,569
Accounts receivable, net	2,493	861
Inventory, net	786	463
Restricted cash	55	0
Total current assets	103,565	109,377
Other assets	5,076	6,235
Deferred offering costs	73	150
Restricted cash	163	218
Intangible assets, net	770	1,056
Operating lease right-of-use asset (See Note 8)	2,646	2,801
Total assets	112,293	119,837
Current liabilities:
Accounts payable	7,419	7,848
Accrued expenses	5,856	5,698
Other liabilities, current portion (See Note 7)	720	0
Operating lease liability, current portion (See Note 8)	269	70
Total current liabilities	14,264	13,616
Other liabilities (See Note 7)	4,898	3,345
Warrant liabilities	27,730	18,062
Convertible debt and derivative liability (See Note 7)	11,032	11,607
Loan payable	34,162	28,745
Operating lease liability (See Note 7)	2,998	3,204
Total liabilities	95,084	78,579
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 5,000,000 shares as of September 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value, 150,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 32,656,242 and 28,705,334 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	36	32
Additional paid-in capital	425,032	400,705
Accumulated deficit	(407,859)	(359,479)
Total stockholders’ equity	17,209	41,258
Total liabilities and stockholders’ equity	$ 112,293	$ 119,837

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	100,000,000
Common stock, shares issued (in shares)	32,656,242	28,705,334
Common stock, shares outstanding (in shares)	32,656,242	28,705,334

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Total revenue	$ 1,557	$ 516	$ 3,567	$ 12,566
Operating expenses:
Cost of product revenues	189	145	432	145
Research and development	6,430	4,401	19,410	16,083
Selling, general and administrative	16,739	15,411	47,001	34,879
Total operating expenses	23,358	19,957	66,843	51,107
Loss from operations	(21,801)	(19,441)	(63,276)	(38,541)
Other expense (income):
Loss on extinguishment of debt	0	0	0	2,725
Amortization of debt issuance costs and discount	396	413	1,194	937
Interest income	(531)	(8)	(724)	(20)
Interest expense	1,379	1,019	3,669	1,678
Warrant liabilities fair value adjustment	6,497	(18,810)	(13,215)	(35,378)
Derivative liabilities fair value adjustment	42	(1,400)	(1,120)	(1,772)
Total other expense (income)	7,783	(18,786)	(10,196)	(31,830)
Loss before taxes	(29,584)	(655)	(53,080)	(6,711)
Income tax benefit	0	(50)	(4,700)	(3,088)
Net loss	$ (29,584)	$ (605)	$ (48,380)	$ (3,623)
Net loss per share attributable to common stockholders - basic
Net loss per share - basic	$ (0.62)	$ (0.02)	$ (1.18)	$ (0.14)
Net loss per share attributable to common stockholders – diluted
Net loss per share – diluted	$ (0.62)	$ (0.06)	$ (1.18)	$ (0.73)
Weighted average common shares outstanding – basic and diluted
Basic	47,503,821	26,616,628	40,965,908	26,147,658
Diluted	47,503,821	27,754,828	40,965,908	26,326,006
Product Revenue, Net
Revenue:
Total revenue	$ 1,557	$ 516	$ 3,567	$ 516
License Agreement Revenue
Revenue:
Total revenue	$ 0	$ 0	$ 0	$ 12,050

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (48,380)	$ (3,623)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	451	133
Stock-based compensation expense	3,232	1,528
Accretion of short-term investment discount	(90)
Amortization of debt issuance costs and discount	1,194	937
Change in fair value of warrant liabilities	(13,215)	(35,378)
Change in fair value of derivative liabilities	(1,120)	(1,772)
Noncash operating lease expense for right-of-use asset	155	149
Loss on extinguishment of debt	0	2,725
Changes in operating assets and liabilities:
Prepaid expenses, accounts receivable, inventory, and other	(1,729)	1,271
Accounts payable, accrued expenses, other liabilities, and other	2,425	4,990
Net cash used in operating activities	(57,077)	(29,040)
Cash flows from investing activities:
Purchase of intangible assets	(9)	(589)
Purchase of short-term investments	(27,380)
Net cash used in investing activities	(27,389)	(589)
Cash flows from financing activities:
Proceeds from common stock issued	47,248	8,027
Payments of offering costs and underwriting discounts and commissions	(3,638)	(151)
Proceeds from loan payable	5,000	30,000
Payments of loan payable issuance costs	(26)	(1,253)
Proceeds from employee stock purchase plan issuances	18	22
Repurchase of shares to satisfy tax withholdings	0	(3)
Net cash provided by financing activities	48,602	36,642
Net (decrease) increase in cash, cash equivalents, and restricted cash	(35,864)	7,013
Cash, cash equivalents, and restricted cash at beginning of period	104,702	93,314
Cash, cash equivalents, and restricted cash at end of period	68,838	100,327
Supplemental cash flow information:
Cash paid for interest	3,308	1,569
Cash received for interest	636	18
Noncash financing and investing activities:
Common stock issued for settlement of senior convertible notes	0	7,452
Purchased intangible assets included in accounts payable and accrued expenses	0	556
Deferred offering and issuance costs included in accounts payable and accrued expenses	0	50
Deferred offering costs reclassified to additional-paid-in capital	77	30
Reclass of warrant liability to additional paid in capital	71	298
Reclass of deferred asset associated with issuance of loan payable to debt discount	206	390
Settlement of liability for exercise of warrants	$ 0	$ 805

Description of Business and Bas

Description of Business and Basis of Preparation	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Preparation	1. Description of Business and Basis of Preparation Organization SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a biotechnology company, headquartered in Jersey City, New Jersey, and is pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (“IV”)/oral agent for severe, hospital-based indications. In June 2021, the U.S. Food and Drug Administration (“FDA”) approved BREXAFEMME ® (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (“VVC”), also known as vaginal yeast infection. The FDA has accepted the Company's submission of a supplemental New Drug Application to expand the label of BREXAFEMME to include the prevention of recurrent VVC. The FDA granted the submission Priority Review and assigned the Prescription Drug User Fee Act target decision date as November 30, 2022. In October 2022, the Company announced that it is actively pursuing a U.S. commercialization partner to out-license BREXAFEMME in order to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications. As a result, the Company has begun to wind down its promotional activities associated with BREXAFEMME, while keeping BREXAFEMME on the market and available to patients. Additionally, the Company will conclude the partnership with its contracted commercial sales partner, Amplity Health ("Amplity"), which is expected to conclude on November 30, 2022, and the Company will undertake a workforce reduction. The Company has incurred significant losses and negative cash flows from operations since its initial public offering in May 2014 and expects to continue to incur losses and negative cash flows for the foreseeable future. As a result, the Company had an accumulated deficit of $ 407.9 million at September 30, 2022 and limited capital resources to fund ongoing operations. These capital resources primarily comprised cash and cash equivalents and short-term investments of $ 96.1 million at September 30, 2022. While the Company believes its capital resources are sufficient to fund the Company’s on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements, the Company's liquidity could be materially affected over this period by: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding; (2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events or unanticipated costs related to its development of ibrexafungerp; (4) its ability to secure a commercialization partner in the U.S. to out-license BREXAFEMME and; (5) any other unanticipated material negative events or costs. One or more of these events or costs could materially affect the Company’s liquidity. If the Company is unable to meet its obligations when they become due, the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to its operating plan. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Intercompany balances and transactions are eliminated in consolidation. New Jersey Technology Business Tax Certificate Transfer (NOL) Program The New Jersey Technology Business Tax Certificate Transfer (NOL) program, administered by the New Jersey Economic Development Authority, enables approved biotechnology companies to sell their unused net operating losses (“NOLs”) and research and development tax credits to unaffiliated, profitable corporate taxpayers in the State of New Jersey. For the nine months ended September 30, 2022, the Company recognized a $ 4.7 million income tax benefit for the sale of a portion of the Company’s unused New Jersey NOLs and research and development credits. Unaudited Condensed Consolidated Financial Information The accompanying unaudited condensed consolidated financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”), as contained in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (the “Codification” or “ASC”) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position, and cash flows. The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the results for the full year or the results for any future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 29, 2022. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Significant estimates and judgements include: revenue recognition including gross to net estimates and the identification of performance obligations in licensing arrangements, determination of the fair value of stock-based compensation grants; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimates and assumptions utilized in measuring the fair values of the warrant and derivative liabilities each reporting period.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The accompanying unaudited condensed consolidated financial statements and notes follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2021, except as described below. Short-Term Investments The Company's held-to-maturity short-term investments in U.S. government securities are carried at amortized cost and any premiums or discounts are amortized or accreted through the maturity date of the investment. Any impairment that is not deemed to be temporary is recognized in the period identified. Basic and Diluted Net Loss per Share of Common Stock The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share . Basic net loss per common share for the three and nine months ended September 30, 2022 and 2021 was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, Earnings Per Share, the weighted average number of common shares outstanding utilized for determining the basic net loss per common share for the three and nine months ended September 30, 2022 includes the outstanding pre-funded warrants to purchase 11,666,667 and 3,200,000 shares of common stock issued in the April 2022 Public Offering and December 2020 public offering, respectively. The outstanding pre-funded warrants to purchase 3,200,000 shares of common stock issued in the December 2020 public offering were included in the three and nine months ended September 30, 2021. Diluted net loss per common share for the three and nine months ended September 30, 2022 and 2021 was determined as follows (in thousands, except share and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net loss $ ( 29,584 ) $ ( 605 ) $ ( 48,380 ) $ ( 3,623 ) Dilutive effect of warrant liability — — — ( 15,719 ) Dilutive effect of convertible debt — ( 988 ) — — Net loss allocated to common shares $ ( 29,584 ) $ ( 1,593 ) $ ( 48,380 ) $ ( 19,342 ) Weighted average common shares outstanding – basic 47,503,821 26,616,628 40,965,908 26,147,658 Dilutive effect of warrant liability — — — 178,348 Dilutive effect of convertible debt — 1,138,200 — — Weighted average common shares outstanding – diluted 47,503,821 27,754,828 40,965,908 26,326,006 Net loss per share – diluted $ ( 0.62 ) $ ( 0.06 ) $ ( 1.18 ) $ ( 0.73 ) The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for the three and nine months ended September 30, 2022 and 2021, as the result would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Outstanding stock options 2,125,002 1,643,506 2,125,002 1,643,506 Outstanding restricted stock units 990,015 149,134 990,015 149,134 Warrants to purchase common stock associated with March 2018 public offering – Series 2 798,810 798,810 798,810 798,810 Warrants to purchase common stock associated with December 2019 public offering — 4,472,205 — 4,472,205 Warrants to purchase common stock associated with December 2020 public offering - Series 1 — 6,439,866 — — Warrants to purchase common stock associated with December 2020 public offering - Series 2 6,800,000 6,800,000 6,800,000 6,800,000 Warrants to purchase common stock associated with April 2022 Public Offering 15,000,000 — 15,000,000 — Warrants to purchase common stock associated with Loan Agreement 198,819 170,410 198,819 170,410 Common stock associated with March 2019 Notes 1,138,200 — 1,138,200 1,138,200 Warrants to purchase common stock associated with Danforth 50,000 — 50,000 — Total 27,100,846 20,473,931 27,100,846 15,172,265 Reclassification of Prior Year Amounts Certain prior year amounts have been reclassified for consistency with the current year presentation. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The amendments in ASU 2016-13 require a financial asset (or group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) (“ASU 2019-10”), which revised the effective dates for ASU 2016-13 for public business entities that meet the SEC definition of a smaller reporting company to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. As a smaller reporting company, the Company is currently evaluating the impact ASU 2016-13 will have on its unaudited condensed consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity (“ASU 2020-06”). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share. The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years. As a smaller reporting company, the Company is currently evaluating the impact ASU 2020-06 will have on its unaudited condensed consolidated financial statements.

Short-term Investments

Short-term Investments	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Short-term Investments	3. Short-term Investments The following table summarizes the short-term investments at September 30, 2022 (in thousands): Amortized Unrealized Unrealized Fair Value As of September 30, 2022 U.S. government securities $ 27,470 $ — $ ( 164 ) $ 27,306 Total short-term investments $ 27,470 $ — $ ( 164 ) $ 27,306 As of September 30, 2022, the Company has $ 27.5 million of held-to-maturity investments with contractual maturities less than one year. The Company carries short-term investments at amortized cost. The fair value of the short-term investments is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): September 30, 2022 December 31, 2021 Prepaid research and development services $ 857 $ 247 Prepaid insurance 543 505 Other prepaid expenses 2,737 2,813 Other current assets 4 4 Total prepaid expenses and other current assets $ 4,141 $ 3,569

Inventory

Inventory	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventory	5. Inventory Inventory consisted of the following (in thousands): September 30, 2022 December 31, 2021 Raw materials $ 5,331 $ 5,162 Work in process — 3 Finished goods 56 127 Total inventory $ 5,387 $ 5,292 As of September 30, 2022 and December 31, 2021, the Company’s inventory consisted of $ 4.6 million and $ 4.8 million, respectively, of raw material that is not expected to be sold in one year and is classified as long term within other assets on the unaudited condensed consolidated balance sheet.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses	6. Accrued Expenses Accrued expenses consisted of the following (in thousands): September 30, 2022 December 31, 2021 Accrued research and development expenses $ 783 $ 1,498 Accrued employee bonus compensation 1,821 2,012 Other accrued expenses 2,580 1,352 Accrued co-pay rebates 672 836 Total accrued expenses $ 5,856 $ 5,698

Borrowings

Borrowings	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Borrowings	7. Borrowings Loan Agreement On May 13, 2021 (the “Closing Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”), as administrative agent and collateral agent (in such capacity, the “Agent”) and a lender, and Silicon Valley Bank, as a lender (“SVB,” and collectively with Hercules, the “Lenders”) for an aggregate principal amount of $ 60.0 million (the “Term Loan”). Pursuant to the Loan Agreement, the Term Loan is available to the Company in four tranches, subject to certain terms and conditions. Under the terms of the Loan Agreement, the Company received an initial tranche of $ 20.0 million from the Lenders on the Closing Date. The second tranche of the Term Loan, consisting of up to an additional $ 10.0 million, became available to the Company upon receipt of approval from the FDA of ibrexafungerp for the treatment of vaginal yeast infections (the “First Performance Milestone”) and was fully funded in June 2021. The third tranche of the Term Loan, consisting of an additional $ 5.0 million, became available to the Company upon (a) the First Performance Milestone and (b) the achievement of the primary endpoint from the Phase 3 study of ibrexafungerp in patients with recurrent vulvovaginal candidiasis, and was fully funded in March 2022. The fourth tranche of the Term Loan, consisting of up to an additional $ 25.0 million, will be available to the Company from January 1, 2022 through December 31, 2023 in $ 5.0 million increments, subject to certain terms and conditions, including in maintaining a ratio of total outstanding Term Loan principal to net product revenues for BREXAFEMME below a certain specified level for a given draw period. The Company estimated the fair value of the loan payable as of September 30, 2022 using a credit spread valuation model and Level 3 inputs which included an implied secured spread, risk free rate, and secured yield of 10.16 %, 4.23 %, and 14.39 %, respectively. As of December 31, 2021, the implied secured spread, risk free rate, and secured yield were 9.30 %, 1.00 %, and 10.30 %. At September 30, 2022 and December 31, 2021, the fair value of the loan payable is $ 33.7 million and $ 29.2 million, respectively. The Term Loan will mature on March 3, 2025 (the “Maturity Date”); provided that, the Maturity Date shall be automatically extended to May 1, 2025 subject to the occurrence of certain conditions set forth in the Loan Agreement. The Term Loan bears interest at a variable annual rate equal to the greater of (a) 9.05 % and (b) the Prime Rate (as reported in the Wall Street Journal) plus 5.80 % (the “Interest Rate”). The Company is making payments of interest only through June 3, 2024, which is further extendable in quarterly increments until the Maturity Date, subject to continued compliance with the financial covenant of the Loan Agreement (the “interest-only period”). After the interest-only period, the principal balance and related interest will be required to be repaid in equal monthly installments and continuing until the Maturity Date. The Loan Agreement contains customary closing fees, prepayment fees and provisions, events of default, and representations, warranties and covenants, including a financial covenant requiring the Company to maintain certain levels of trailing three-month net product revenue solely from the sale of ibrexafungerp commencing on September 30, 2022. The financial covenant will be waived at any time in which the Company maintains unrestricted and unencumbered cash in accounts maintained with SVB equal to at least 50.0 % of the total outstanding Term Loan principal amount, subject to certain requirements. Future principal debt payments on the currently outstanding loan payable as of September 30, 2022 are as follows (in thousands): 2022 — 2023 — 2024 23,684 2025 11,316 Total principal payments 35,000 Final fee due at maturity 1,383 Total principal and final fee payment 36,383 Unamortized discount and debt issuance costs ( 2,221 ) Less current portion — Loan payable, long term $ 34,162 April 2020 Note Purchase Agreement On April 9, 2020 , the Company entered into the April 2020 Note Purchase Agreement with Puissance Life Science Opportunities Fund VI (“Puissance”) and issued and sold to Puissance $ 10.0 million aggregate principal amount of its April 2020 Notes, resulting in net proceeds of approximately $ 9.5 million after deducting $ 0.5 million for an advisory fee and other issuance costs. In January 2021, Puissance converted the remaining $ 6.0 million of the April 2020 Notes for 959,080 shares of common stock. Upon conversion of the $ 6.0 million of the April 2020 Notes, the Company recognized a $ 2.7 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of $ 4.8 million and the fair value of the consideration issued of $ 7.5 million. March 2019 Note Purchase Agreement On March 7, 2019 , the Company entered into a Senior Convertible Note Purchase Agreement (the “March 2019 Note Purchase Agreement”) with Puissance. Pursuant to the March 2019 Note Purchase Agreement, on March 7, 2019, the Company issued and sold to Puissance $ 16.0 million aggregate principal amount of its 6.0% Senior Convertible Notes due 2025 (“March 2019 Notes”), resulting in $ 14.7 million in net proceeds after deducting $ 1.3 million for an advisory fee and other issuance costs. As of September 30, 2022 and December 31, 2021, the Company’s March 2019 Notes consists of the convertible debt balance of $ 10.8 million and $ 10.2 million, presented net of the unamortized debt issuance costs allocated to the convertible debt of $ 0.3 million, and the bifurcated embedded conversion option derivative liability of $ 0.2 million and $ 1.4 million, respectively. In connection with the Company’s issuance of its March 2019 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Company’s balance sheet in accordance with ASC 815, Derivatives and Hedging , at its initial fair value of $ 7.0 million as the interest make-whole provision is settled in shares of common stock. The convertible debt and derivative liability associated with the March 2019 Notes are presented in total on the accompanying unaudited condensed consolidated balance sheets as the convertible debt and derivative liability. The derivative liability will be remeasured at each reporting period using the binomial lattice model with changes in fair value recorded in the statements of operations in other (income) expense. For the three months ended September 30, 2022 and 2021, the Company recognized a loss of $ 42,000 and a gain of $ 1.4 million, respectively, on the fair value adjustment for the derivative liability. For the nine months ended September 30, 2022 and 2021, the Company recognized gains of $ 1.1 million and $ 1.9 million, respectively, on the fair value adjustment for the derivative liability. For both the three months ended September 30, 2022 and 2021, the Company recognized $ 0.2 million in amortization of debt issuance costs and discount related to the March 2019 Notes. For the nine months ended September 30, 2022 and 2021, the Company recognized $ 0.5 million and $ 0.7 million, respectively, in amortization of debt issuance costs and discount related to the March 2019 Notes. The Company estimated the fair value of the convertible debt and derivative liability for the March 2019 Notes using a binomial lattice valuation model and Level 3 inputs. At September 30, 2022 and December 31, 2021, the fair value of the convertible debt and derivative liability for the March 2019 Notes is $ 10.6 million and $ 12.3 million, respectively. The March 2019 Notes bear interest at a rate of 6.0 % per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025 , unless earlier converted, redeemed or repurchased. The March 2019 Notes constitute general, senior unsecured obligations of the Company. Other Liabilities In February 2021, the Company partnered with Amplity for the commercial launch of BREXAFEMME for the treatment of VVC. In October 2022, the Company announced that it is actively pursuing a U.S. commercialization partner to out-license BREXAFEMME to in order to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications. As a result, the Company has begun to wind down its promotional activities associated with BREXAFEMME, while keeping BREXAFEMME on the market and available to patients. As a result, the Company will conclude the partnership with Amplity, which is expected to conclude on November 30, 2022. Under the terms of the 5-year agreement as currently in effect (the "Amplity Agreement"), the Company was to utilize Amplity’s commercial execution and resources for sales force, remote engagement, training, market access and select operations services. The Company maintains full ownership of ibrexafungerp. Amplity deferred a portion of its direct service fees (“Deferred Fees”) in the first two years (2021 and 2022) which the Company is to repay according to the terms of the Amplity Agreement and the Loan Agreement, including related agreements. As of September 30, 2022 and December 31, 2021, Deferred Fees of $ 4.9 million and $ 3.3 million, respectively, are recognized as long term other liabilities in the unaudited condensed consolidated balance sheet. The Deferred Fees represent a debt obligation as of September 30, 2022 given the Amplity Agreement had not been terminated as of September 30, 2022. The Deferred Fees accrue interest at an annual rate of 12.75 % and will be compounded quarterly, at the end of each quarter. Interest expense is recognized using the effective interest method. The Company will repay the Deferred Fees plus accrued interest in quarterly installments at the end of each calendar quarter beginning in 2023. The total amount of Deferred Fees plus accrued interest as of December 31, 2022, will serve as the basis for repayment (the “Repayment Basis”), which shall be repaid in equal installments at the end of a given quarter calculated as follows: 15 % of the Repayment Basis will be repaid in 2023; 50 % of the Repayment Basis will be repaid in 2024; and 35 % of the Repayment Basis will be repaid in 2025. As of September 30, 2022, the Company is obligated to repay $ 1.0 million in 2023, $ 2.6 million in 2024, and $ 2.0 million in 2025. If the Amplity Agreement is terminated, the Deferred Fees become immediately due, subject to the terms of the Loan Agreement and related agreements.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Leases On March 1, 2018, the Company entered into a long-term lease agreement for approximately 19,275 square feet of office space in Jersey City, New Jersey, that the Company identified as an operating lease under ASC 842 (the “Lease”). The lease term is eleven years from August 1, 2018, the commencement date, with total lease payments of $ 7.3 million over the lease term. The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $ 0.3 million, which was reduced by fifty-five thousand dollars on the first anniversary of the commencement date. The security deposit will continue to be reduced by fifty-five thousand dollars every two years on the commencement date anniversary for eight years. The security deposit is classified as restricted cash in the accompanying unaudited condensed consolidated balance sheets. The following table summarizes certain quantitative information associated with the amounts recognized in the unaudited condensed consolidated financial statements for the Lease (dollars in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating lease cost $ 166 $ 166 $ 498 $ 498 Variable lease cost 8 9 13 18 Total operating lease expense $ 174 $ 175 $ 511 $ 516 Cash paid for amounts included in the measurement of operating lease liability $ 118 $ 116 $ 350 $ 343 September 30, 2022 December 31, 2021 Remaining Lease term (years) 6.84 7.59 Discount rate 15 % 15 % Future minimum lease payments for the Lease as of September 30, 2022 are as follows (in thousands): September 30, 2022 2022 $ 177 2023 715 2024 730 2025 744 2026 759 Thereafter 2,030 Total $ 5,155 The presentations of the operating lease liability as of September 30, 2022 are as follows (in thousands): September 30, 2022 Present value of future minimum lease payments $ 3,267 Operating lease liability, current portion $ 269 Operating lease liability, long-term portion 2,998 Total operating lease liability $ 3,267 Difference between future minimum lease payments and discounted cash flows $ 1,888 License Arrangement with Potential Future Expenditures As of September 30, 2022, the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, as amended, that involves potential future expenditures. Under the license arrangement, executed in May 2013, the Company exclusively licensed from Merck its rights to ibrexafungerp in the field of human health. In January 2014, Merck assigned the patents related to ibrexafungerp that it had exclusively licensed to the Company. Ibrexafungerp is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck was originally eligible to receive milestone payments from the Company that could total $ 19.0 million upon occurrence of specific events, including initiation of a Phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets, and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of ibrexafungerp. The aggregate royalties are mid- to high-single digits. In December 2014, the Company and Merck entered into an amendment to the license agreement that deferred the remittance of a milestone payment due to Merck, such that no amount would be due upon initiation of the first Phase 2 clinical trial of a product containing the ibrexafungerp compound (the “Deferred Milestone”). The amendment also increased, in an amount equal to the Deferred Milestone, the milestone payment that would be due upon initiation of the first Phase 3 clinical trial of a product containing the ibrexafungerp compound. In December 2016 and January 2018, the Company entered into second and third amendments to the license agreement with Merck which clarified what would constitute the initiation of a Phase 3 clinical trial for the purpose of milestone payment. In January 2019, a milestone payment became due to Merck as a result of the initiation of the VANISH Phase 3 VVC program and was paid in March 2019. On December 2, 2020, the Company entered into a fourth amendment to the license agreement with Merck. The amendment eliminates two cash milestone payments that the Company would have paid to Merck upon the first filing of an NDA, triggered by the FDA acceptance for filing of the Company’s NDA for ibrexafungerp for the treatment of VVC, and first marketing approval in the U.S. Such cash milestone payments would have been creditable against future royalties owed to Merck on net sales of ibrexafungerp. With the amendment, these milestones will not be paid in cash and, accordingly, credits will not accrue. Pursuant to the amendment, the Company will also forfeit the credits against future royalties that it had accrued from a prior milestone payment already paid to Merck. All other key terms of the license agreement are unchanged.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders' Equity	9. Stockholders’ Equity Authorized, Issued, and Outstanding Common Stock The Company’s authorized common stock has a par value of $ 0.001 per share and consists of 150,000,000 and 100,000,000 shares as of September 30, 2022, and December 31, 2021, respectively; 32,656,242 and 28,705,334 shares were issued and outstanding at September 30, 2022, and December 31, 2021, respectively. In September 2022, the Company amended its Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from 100,000,000 to 150,000,000 . T he following table summarizes common stock share activity for the three and nine months ended September 30, 2022 and 2021 (dollars in thousands): Three Months Ended September 30, 2022 Shares of Common Additional Accumulated Total Balance, June 30, 2022 32,596,403 $ 36 $ 423,719 $ ( 378,275 ) $ 45,480 Net loss — — — ( 29,584 ) ( 29,584 ) Stock-based compensation expense — — 1,210 — 1,210 Common stock issued through employee stock purchase plan 3,714 — 8 — 8 Common stock issued, net of expenses 50,000 — 95 — 95 Common stock issued for vested restricted stock units 6,125 — — — — Balance, September 30, 2022 32,656,242 $ 36 $ 425,032 $ ( 407,859 ) $ 17,209 Three Months Ended September 30, 2021 Shares of Common Additional Accumulated Total Balance, June 30, 2021 23,147,552 $ 26 $ 361,925 $ ( 329,631 ) $ 32,320 Net loss — — — ( 605 ) ( 605 ) Stock-based compensation expense — — 588 — 588 Common stock issued through employee stock purchase plan 2,759 — 13 — 13 Common stock issued, net of expenses 733,937 1 5,300 — 5,301 Common stock issued for vested restricted stock units 1,322 — ( 3 ) — ( 3 ) Balance, September 30, 2021 23,885,570 $ 27 $ 367,823 $ ( 330,236 ) $ 37,614 Nine Months Ended September 30, 2022 Shares of Common Additional Accumulated Total Balance, December 31, 2021 28,705,334 $ 32 $ 400,705 $ ( 359,479 ) $ 41,258 Net loss — — — ( 48,380 ) ( 48,380 ) Stock-based compensation expense — — 3,232 — 3,232 Common stock issued through employee stock purchase plan 6,834 — 18 — 18 Common stock issued, net of expenses 3,895,943 4 21,006 — 21,010 Common stock issued for vested restricted stock units 48,131 — — — — Vested Loan Agreement warrants — — 71 — 71 Balance, September 30, 2022 32,656,242 $ 36 $ 425,032 $ ( 407,859 ) $ 17,209 Nine Months Ended September 30, 2021 Shares of Common Additional Accumulated Total Balance, December 31, 2020 19,663,698 $ 20 $ 349,351 $ ( 326,613 ) $ 22,758 Net loss — — — ( 3,623 ) ( 3,623 ) Stock-based compensation expense — — 1,528 — 1,528 Common stock issued through employee stock purchase plan 4,943 — 22 — 22 Common stock issued, net of expenses 3,250,739 6 8,707 — 8,713 Common stock issued for conversion of April 2020 Notes 959,080 1 7,452 — 7,453 Common stock issued for vested restricted stock units 7,110 — ( 3 ) — ( 3 ) Vested Loan Agreement warrants — — 766 — 766 Balance, September 30, 2021 23,885,570 $ 27 $ 367,823 $ ( 330,236 ) $ 37,614 Shares Reserved for Future Issuance The Company had reserved shares of common stock for future issuance as follows: September 30, 2022 December 31, 2021 Outstanding stock options 2,125,002 1,542,126 Outstanding restricted stock units 990,015 133,834 Warrants to purchase common stock associated with March 2018 public offering – Series 2 798,810 798,810 Warrants to purchase common stock associated with December 2020 public offering - Series 2 6,800,000 6,800,000 Prefunded warrants to purchase common stock associated with December 2020 public offering 3,200,000 3,200,000 Warrants to purchase common stock associated with April 2022 Public Offering 15,000,000 — Prefunded warrants to purchase common stock associated with April 2022 Public Offering 11,666,667 — Warrants to purchase common stock associated with Loan Agreement 198,819 170,410 Warrant to purchase common stock associated with Danforth 50,000 50,000 For possible future issuance for the conversion of the March 2019 Notes 1,138,200 1,138,200 For possible future issuance under 2014 Plan (Note 10) 62,995 295,220 For possible future issuance under employee stock purchase plan — 3,893 For possible future issuance under 2015 Plan (Note 10) 128,250 235,000 Total common shares reserved for future issuance 42,158,758 14,367,493 April 2022 Public Offering On April 22, 2022, the Company entered into an Equity Underwriting Agreement (the “Underwriting Agreement”) with Guggenheim Securities, LLC, as representative of the several underwriters (the “Underwriters”), relating to the offering, issuance and sale (the “April 2022 Public Offering”) of (a) 3,333,333 shares of the Company’s common stock, par value $ 0.001 per share, (b) pre-funded warrants, in lieu of common stock, to purchase 11,666,667 shares of the Company’s common stock, par value $ 0.001 per share, and (c) warrants, which will accompany the common stock or pre-funded warrants, to purchase up to an aggregate of 15,000,000 shares of the Company’s common stock. The pre-funded warrants entitle the holders to purchase up to 11,666,667 shares of common stock and have an unlimited term and an exercise price of $ 0.001 per share. The warrants entitle the holders to purchase up to an aggregate of 15,000,000 shares of common stock and have a seven-year term and an exercise price of $ 3.45 per share. The warrants that accompany the pre-funded warrants have an additional provision entitling the holder thereof to purchase a pre-funded warrant rather than a share of common stock at the warrant exercise price less the exercise price of the pre-funded warrant purchased. Each warrant is exercisable immediately upon issuance, subject to certain limitations on beneficial ownership. The price to the public in the April 2022 Public Offering was $ 3.00 per share of common stock and accompanying warrants, or in the case of pre-funded warrants, $ 2.999 per pre-funded warrant and accompanying warrants, which resulted in $ 41.8 million of net proceeds to the Company after deducting the underwriting discount and offering expenses. The prefunded warrants are classified as equity in accordance with ASC 815, Derivatives and Hedging given the prefunded warrants are indexed to the Company’s own shares of common stock and meet the requirements to be classified in equity. The prefunded warrants were recorded at their relative fair value at issuance in the stockholders’ equity section of the balance sheet and the prefunded warrants are considered outstanding shares in the basic earnings per share calculation for the three and nine months ended September 30, 2022 given their nominal exercise price. Common Stock Purchase Agreement and Sales Agreements On April 10, 2020, the Company entered into the Common Stock Purchase Agreement with Aspire Capital (the “Common Stock Purchase Agreement”) pursuant to which the Company had the right to sell to Aspire Capital from time to time in its sole discretion up to $ 20.0 million in shares of the Company’s common stock, subject to certain limitations and conditions set forth in the Common Stock Purchase Agreement. The Common Stock Purchase Agreement expired in October 2022. During the three and nine months ended September 30, 2022, the Company sold 50,000 and 425,000 shares of its common stock under the Common Stock Purchase Agreement for gross proceeds of $ 0.1 million and $ 1.6 million, respectively. During both the three and nine months ended September 30, 2021, the Company sold 400,000 of its common stock under the Common Stock Purchase Agreement for gross proceeds of $ 2.6 million. During the three and nine months ended September 30, 2022, the Company sold zero and 137,610 shares of its common stock and received net proceeds of zero and $ 0.7 million, respectively, under the Controlled Equity Offering SM Sales Agreements with Cantor Fitzgerald & Co. and Ladenburg Thalmann & Co. Inc. (the “Sales Agreements”). During the three and nine months ended September 30, 2021, the Company sold 333,937 and 430,605 shares of its common stock and received net proceeds of $ 1.9 million and $ 2.5 million under the Sales Agreements. Warrants Associated with the March 2018, December 2020 and April 2022 Public Offerings The outstanding warrants associated with the March 2018 and December 2020 public offerings contain a provision where the warrant holder has the option to receive cash, equal to the Black-Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, Distinguishing Liabilities from Equity, requires that these warrants be classified as liabilities. The fair values of these warrants have been determined using the Black-Scholes valuation model, and the changes in the fair value are recorded in the accompanying unaudited condensed consolidated statements of operations. The outstanding warrants associated with the April 2022 public offering meet the definition of a derivative pursuant to ASC 815, Derivatives and Hedging , and do not meet the derivative scope exception given the warrants do not qualify under the indexation guidance. As a result, the April 2022 public offering warrants were initially recognized as liabilities and measured at fair value using the Black-Scholes valuation model. Issuance costs of $ 1.7 million initially allocated to the April 2022 public offering warrants were written off and recognized in the warrant liabilities fair value adjustment in the nine months ended September 30, 2022. During the three months ended September 30, 2022 and 2021, the Company recognized a loss of $ 6.5 million and a gain of $ 18.8 million on the warrant liabilities fair value adjustment, respectively. During the nine months ended September 30, 2022 and 2021, the Company recognized gains of $ 13.2 million and $ 35.4 million on the warrant liabilities fair value adjustment. As of September 30, 2022 and December 31, 2021, the fair value of the warrant liabilities was $ 27.7 million and $ 18.1 million, respectively. Warrants Associated with Loan Agreement In connection with the entry into the Loan Agreement, the Company issued to each of Hercules and SVB a warrant (collectively, the “Warrants”) to purchase shares of the Company’s common stock, par value $ 0.001 per share (the “Shares”). The amount of shares that may be purchased for the Warrants, collectively between Hercules and SVB, will not exceed 0.04 multiplied by the aggregate amount of the term loan advances, divided by the exercise price of the Warrants. At the closing of the Loan Agreement, the Company issued 113,607 warrants to purchase shares of the Company’s common stock and recognized the initial warrants at their relative fair value in shareholder's equity. Upon the funding of the $ 10.0 million and $ 5.0 million for the second and third tranches in June 2021 and March 2022, respectively, the associated warrant liabilities of $ 0.3 million and $ 0.1 million, respectively, were reclassed to additional paid in capital at settlement. In June 2021 and March 2022, 56,803 and 28,409 warrants to purchase shares of the Company’s common stock were issued upon vesting of the second and third tranches, respectively.

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	10. Stock-based Compensation Pursuant to the terms of the Company’s 2014 Equity Incentive Plan (“2014 Plan”), on January 1, 2022 and 2021, the Company automatically added 1,148,213 and 786,547 shares to the total number shares of common stock available for future issuance under the 2014 Plan, respectively. As of September 30, 2022, there were 62,995 shares of common stock available for future issuance under the 2014 Plan. As of September 30, 2022, there were 128,250 shares of common stock available for future issuance under the Company’s 2015 Inducement Award Plan (“2015 Plan”). During the nine months ended September 30, 2022 and 2021, there were options to purchase 109,000 and 182,600 shares of the Company’s common stock granted under the 2015 Plan, respectively. The activity for the Company’s 2009 Stock Option Plan, 2014 Plan, and 2015 Plan, for the nine months ended September 30, 2022, is summarized as follows: Number of Weighted- Weighted- Aggregate Outstanding — December 31, 2021 1,542,126 $ 14.89 7.45 $ 42 Granted 664,000 $ 4.15 Forfeited/Cancelled ( 81,124 ) $ 7.42 Outstanding — September 30, 2022 2,125,002 $ 11.82 7.61 $ 49 Exercisable — September 30, 2022 1,052,080 $ 18.11 6.30 $ — Vested or expected to vest — September 30, 2022 2,125,002 $ 11.82 7.61 $ 49 Restricted stock unit (“RSU”) activity under the 2014 Plan and 2015 Plan for the nine months ended September 30, 2022, is summarized as follows: Number of Weighted Non-vested at December 31, 2021 133,834 $ 7.98 Granted 943,465 $ 5.35 Vested ( 48,131 ) $ 8.29 Forfeited ( 39,153 ) $ 6.28 Non-vested at September 30, 2022 990,015 $ 5.52 The fair value of RSUs is based on the market price of the Company’s common stock on the date of grant. RSUs generally vest 25 % annually over a four-year period from the date of grant. Upon vesting, the RSUs are net share settled to cover the required withholding tax with the remaining shares issued to the holder. The Company recognizes compensation expense for such awards ratably over the corresponding vesting period. Compensation Cost The compensation cost that has been charged against income for stock awards under the 2014 Plan and the 2015 Plan was $ 1.0 million and $ 0.6 million for the three months ended September 30, 2022 and 2021, respectively, and $ 3.1 million and $ 1.5 million for the nine months ended September 30, 2022 and 2021, respectively. The total income tax benefit recognized in the statements of operations for share-based compensation arrangements was zero for each of the three and nine months ended September 30, 2022 and 2021. Stock-based compensation expense related to stock options is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Research and development $ 327 $ 174 $ 955 $ 436 Selling, general and administrative 710 414 2,104 1,092 Total $ 1,037 $ 588 $ 3,059 $ 1,528

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	11. Fair Value Measurements The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of September 30, 2022 and December 31, 2021 for financial instruments measured at fair value on a recurring basis (in thousands): Fair Value Hierarchy Classification Balance Quoted Significant Significant September 30, 2022 Cash $ ( 59 ) $ ( 59 ) — — Restricted cash 218 218 — — Money market funds 68,679 68,679 — — Total assets $ 68,838 $ 68,838 — — Warrant liabilities $ 27,730 — — $ 27,730 Derivative liability 238 — — 238 Total liabilities $ 27,968 — — $ 27,968 December 31, 2021 Cash $ 310 $ 310 — — Restricted cash 218 218 — — Money market funds 104,187 104,187 — — Total assets $ 104,715 $ 104,715 — — Warrant liabilities $ 18,062 — — $ 18,062 Derivative liability 1,358 — — 1,358 Total liabilities $ 19,420 — — $ 19,420 The Company measures cash equivalents at fair value on a recurring basis. The fair value of cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. Level 3 financial liabilities consist of the warrant liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The Company uses the Black-Scholes option valuation model to value the Level 3 warrant liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as volatility. The unobservable input for all of the Level 3 warrant liabilities includes volatility. The historical and implied volatility of the Company, using its closing common stock prices and market data, is utilized to reflect future volatility over the expected term of the warrants. At September 30, 2022, the range and weighted average of the Level 3 volatilities utilized in the Black-Scholes model to fair value the warrant liabilities were 81.7 % to 84.8 % and 84.7 %, respectively. The Company utilizes a probability assessment to estimate the likelihood of vesting for the remaining Loan Agreement warrants and allocated the probability of occurrence percentage to the fair values calculated. The Company uses the binomial lattice valuation model to value the Level 3 derivative liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, dividend yield, risk-free rate, adjusted equity volatility, credit rating, market credit spread, and estimated effective yield. The unobservable inputs associated with the Level 3 derivative liabilities are adjusted equity volatility, market credit spread, and estimated yield. As of September 30, 2022, these inputs were 65.7 %, 1,544 basis points, and 19.7 %, respectively. The senior convertible notes are initially fair valued using the binomial lattice model and with the straight debt fair value calculated using the discounted cash flow method. The residual difference represents the fair value of the embedded derivative liabilities and the fair value of the embedded derivative liabilities are reassessed using the binomial lattice valuation model on a quarterly basis. A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands): Warrant Liabilities Balance – December 31, 2021 $ 18,062 April 2022 Public Offering warrant issuance 24,704 Loan Agreement warrants ( 71 ) Gain adjustment to fair value ( 14,965 ) Balance – September 30, 2022 $ 27,730 Derivative Liability Balance – December 31, 2021 $ 1,358 Gain adjustment to fair value ( 1,120 ) Balance – September 30, 2022 $ 238

Revenue

Revenue	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue	12. Revenue Product Revenue, Net Net product revenue was $ 1.6 million and $ 3.6 million for the three and nine months ended September 30, 2022. Products are sold primarily to wholesalers and specialty pharmacies. Revenue is reduced from wholesaler list price at the time of recognition for expected chargebacks, rebates, discounts, incentives, and returns, which are referred to as gross to net (“GTN”) adjustments. These reductions are currently attributed to various commercial arrangements. Chargebacks and discounts are recognized as a reduction in accounts receivable or as accrued expenses based on their nature and settled through the issuance of credits to the customer or through cash payments to the customer, respectively. All other returns, rebates, and incentives are reflected as accrued expenses and settled through cash payments to the customer. Three wholesalers comprised 45 %, 29 %, and 20 % of the Company’s gross revenue for the nine months ended September 30, 2022. The following table summarizes activity in each of the Company’s product revenue provision and allowance categories as of September 30, 2022 (in thousands): Discounts and Chargebacks (1) Product Returns (2) Rebates and Incentives (3) Total Balance as of December 31, 2021 $ 249 $ 21 $ 1,110 $ 1,380 Provision related to current period revenue 1,124 38 2,998 4,160 Changes in estimate related to prior period revenue ( 31 ) — 55 24 Credit/payments ( 742 ) — ( 2,982 ) ( 3,724 ) Balance as of September 30, 2022 $ 600 $ 59 $ 1,181 $ 1,840 (1) Discounts and chargebacks include fees for wholesaler fees, prompt pay and other discounts, and chargebacks. Discounts and chargebacks are deducted from gross revenue at the time revenues are recognized and are included as a reduction in accounts receivable or as an accrued expense based on their nature on the Company’s unaudited condensed consolidated balance sheet. (2) Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Company’s unaudited condensed consolidated balance sheet. (3) Rebates and incentives include rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Company’s unaudited condensed consolidated balance sheets. License Agreement Revenue In February 2021, the Company entered into an Exclusive License and Collaboration Agreement (the “Agreement”) with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited (collectively, “Hansoh”), pursuant to which the Company granted to Hansoh an exclusive license to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan (the “Territory”). The Company also granted to Hansoh a non-exclusive license to manufacture ibrexafungerp solely for development and commercialization in the Territory. For the three and nine months ended September 30, 2022, there was no license agreement revenue recognized associated with the Agreement given the variable consideration was fully constrained as of September 30, 2022. For the nine months ended September 30, 2021, the Company recognized license agreement revenue of $ 12.1 million which included the fixed upfront cash payment of $ 10.0 million, an additional amount that was payable upon the transfer of certain data related to the manufacturing license, and $ 1.1 million related to withholding tax obligations that Hansoh remitted on behalf of the Company.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Short-Term Investments	Short-Term Investments The Company's held-to-maturity short-term investments in U.S. government securities are carried at amortized cost and any premiums or discounts are amortized or accreted through the maturity date of the investment. Any impairment that is not deemed to be temporary is recognized in the period identified.
Basic and Diluted Net Loss per Share of Common Stock	Basic and Diluted Net Loss per Share of Common Stock The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share . Basic net loss per common share for the three and nine months ended September 30, 2022 and 2021 was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, Earnings Per Share, the weighted average number of common shares outstanding utilized for determining the basic net loss per common share for the three and nine months ended September 30, 2022 includes the outstanding pre-funded warrants to purchase 11,666,667 and 3,200,000 shares of common stock issued in the April 2022 Public Offering and December 2020 public offering, respectively. The outstanding pre-funded warrants to purchase 3,200,000 shares of common stock issued in the December 2020 public offering were included in the three and nine months ended September 30, 2021. Diluted net loss per common share for the three and nine months ended September 30, 2022 and 2021 was determined as follows (in thousands, except share and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net loss $ ( 29,584 ) $ ( 605 ) $ ( 48,380 ) $ ( 3,623 ) Dilutive effect of warrant liability — — — ( 15,719 ) Dilutive effect of convertible debt — ( 988 ) — — Net loss allocated to common shares $ ( 29,584 ) $ ( 1,593 ) $ ( 48,380 ) $ ( 19,342 ) Weighted average common shares outstanding – basic 47,503,821 26,616,628 40,965,908 26,147,658 Dilutive effect of warrant liability — — — 178,348 Dilutive effect of convertible debt — 1,138,200 — — Weighted average common shares outstanding – diluted 47,503,821 27,754,828 40,965,908 26,326,006 Net loss per share – diluted $ ( 0.62 ) $ ( 0.06 ) $ ( 1.18 ) $ ( 0.73 ) The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for the three and nine months ended September 30, 2022 and 2021, as the result would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Outstanding stock options 2,125,002 1,643,506 2,125,002 1,643,506 Outstanding restricted stock units 990,015 149,134 990,015 149,134 Warrants to purchase common stock associated with March 2018 public offering – Series 2 798,810 798,810 798,810 798,810 Warrants to purchase common stock associated with December 2019 public offering — 4,472,205 — 4,472,205 Warrants to purchase common stock associated with December 2020 public offering - Series 1 — 6,439,866 — — Warrants to purchase common stock associated with December 2020 public offering - Series 2 6,800,000 6,800,000 6,800,000 6,800,000 Warrants to purchase common stock associated with April 2022 Public Offering 15,000,000 — 15,000,000 — Warrants to purchase common stock associated with Loan Agreement 198,819 170,410 198,819 170,410 Common stock associated with March 2019 Notes 1,138,200 — 1,138,200 1,138,200 Warrants to purchase common stock associated with Danforth 50,000 — 50,000 — Total 27,100,846 20,473,931 27,100,846 15,172,265
Reclassification of Prior Year Amounts	Reclassification of Prior Year Amounts Certain prior year amounts have been reclassified for consistency with the current year presentation.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The amendments in ASU 2016-13 require a financial asset (or group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) (“ASU 2019-10”), which revised the effective dates for ASU 2016-13 for public business entities that meet the SEC definition of a smaller reporting company to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. As a smaller reporting company, the Company is currently evaluating the impact ASU 2016-13 will have on its unaudited condensed consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity (“ASU 2020-06”). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share. The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years. As a smaller reporting company, the Company is currently evaluating the impact ASU 2020-06 will have on its unaudited condensed consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Diluted Net Loss Per Common Share	The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share . Basic net loss per common share for the three and nine months ended September 30, 2022 and 2021 was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, Earnings Per Share, the weighted average number of common shares outstanding utilized for determining the basic net loss per common share for the three and nine months ended September 30, 2022 includes the outstanding pre-funded warrants to purchase 11,666,667 and 3,200,000 shares of common stock issued in the April 2022 Public Offering and December 2020 public offering, respectively. The outstanding pre-funded warrants to purchase 3,200,000 shares of common stock issued in the December 2020 public offering were included in the three and nine months ended September 30, 2021. Diluted net loss per common share for the three and nine months ended September 30, 2022 and 2021 was determined as follows (in thousands, except share and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net loss $ ( 29,584 ) $ ( 605 ) $ ( 48,380 ) $ ( 3,623 ) Dilutive effect of warrant liability — — — ( 15,719 ) Dilutive effect of convertible debt — ( 988 ) — — Net loss allocated to common shares $ ( 29,584 ) $ ( 1,593 ) $ ( 48,380 ) $ ( 19,342 ) Weighted average common shares outstanding – basic 47,503,821 26,616,628 40,965,908 26,147,658 Dilutive effect of warrant liability — — — 178,348 Dilutive effect of convertible debt — 1,138,200 — — Weighted average common shares outstanding – diluted 47,503,821 27,754,828 40,965,908 26,326,006 Net loss per share – diluted $ ( 0.62 ) $ ( 0.06 ) $ ( 1.18 ) $ ( 0.73 )
Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding	The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for the three and nine months ended September 30, 2022 and 2021, as the result would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Outstanding stock options 2,125,002 1,643,506 2,125,002 1,643,506 Outstanding restricted stock units 990,015 149,134 990,015 149,134 Warrants to purchase common stock associated with March 2018 public offering – Series 2 798,810 798,810 798,810 798,810 Warrants to purchase common stock associated with December 2019 public offering — 4,472,205 — 4,472,205 Warrants to purchase common stock associated with December 2020 public offering - Series 1 — 6,439,866 — — Warrants to purchase common stock associated with December 2020 public offering - Series 2 6,800,000 6,800,000 6,800,000 6,800,000 Warrants to purchase common stock associated with April 2022 Public Offering 15,000,000 — 15,000,000 — Warrants to purchase common stock associated with Loan Agreement 198,819 170,410 198,819 170,410 Common stock associated with March 2019 Notes 1,138,200 — 1,138,200 1,138,200 Warrants to purchase common stock associated with Danforth 50,000 — 50,000 — Total 27,100,846 20,473,931 27,100,846 15,172,265

Short-term Investments (Tables)

Short-term Investments (Tables)	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
summary of short-term investments	The following table summarizes the short-term investments at September 30, 2022 (in thousands): Amortized Unrealized Unrealized Fair Value As of September 30, 2022 U.S. government securities $ 27,470 $ — $ ( 164 ) $ 27,306 Total short-term investments $ 27,470 $ — $ ( 164 ) $ 27,306

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): September 30, 2022 December 31, 2021 Prepaid research and development services $ 857 $ 247 Prepaid insurance 543 505 Other prepaid expenses 2,737 2,813 Other current assets 4 4 Total prepaid expenses and other current assets $ 4,141 $ 3,569

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted of the following (in thousands): September 30, 2022 December 31, 2021 Raw materials $ 5,331 $ 5,162 Work in process — 3 Finished goods 56 127 Total inventory $ 5,387 $ 5,292

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following (in thousands): September 30, 2022 December 31, 2021 Accrued research and development expenses $ 783 $ 1,498 Accrued employee bonus compensation 1,821 2,012 Other accrued expenses 2,580 1,352 Accrued co-pay rebates 672 836 Total accrued expenses $ 5,856 $ 5,698

Borrowings (Tables)

Borrowings (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Future Principal Debt Payments On Currently Outstanding Loan Payable	Future principal debt payments on the currently outstanding loan payable as of September 30, 2022 are as follows (in thousands): 2022 — 2023 — 2024 23,684 2025 11,316 Total principal payments 35,000 Final fee due at maturity 1,383 Total principal and final fee payment 36,383 Unamortized discount and debt issuance costs ( 2,221 ) Less current portion — Loan payable, long term $ 34,162

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Summary of Quantitative Information Associated with Amounts Recognized in Unaudited Condensed Consolidated Financial Statements for Lease	The following table summarizes certain quantitative information associated with the amounts recognized in the unaudited condensed consolidated financial statements for the Lease (dollars in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating lease cost $ 166 $ 166 $ 498 $ 498 Variable lease cost 8 9 13 18 Total operating lease expense $ 174 $ 175 $ 511 $ 516 Cash paid for amounts included in the measurement of operating lease liability $ 118 $ 116 $ 350 $ 343 September 30, 2022 December 31, 2021 Remaining Lease term (years) 6.84 7.59 Discount rate 15 % 15 %
Future Minimum Lease Payments	Future minimum lease payments for the Lease as of September 30, 2022 are as follows (in thousands): September 30, 2022 2022 $ 177 2023 715 2024 730 2025 744 2026 759 Thereafter 2,030 Total $ 5,155
Presentation of Operating Lease Liability	The presentations of the operating lease liability as of September 30, 2022 are as follows (in thousands): September 30, 2022 Present value of future minimum lease payments $ 3,267 Operating lease liability, current portion $ 269 Operating lease liability, long-term portion 2,998 Total operating lease liability $ 3,267 Difference between future minimum lease payments and discounted cash flows $ 1,888

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Summary of Common Stock Shares Activity	he following table summarizes common stock share activity for the three and nine months ended September 30, 2022 and 2021 (dollars in thousands): Three Months Ended September 30, 2022 Shares of Common Additional Accumulated Total Balance, June 30, 2022 32,596,403 $ 36 $ 423,719 $ ( 378,275 ) $ 45,480 Net loss — — — ( 29,584 ) ( 29,584 ) Stock-based compensation expense — — 1,210 — 1,210 Common stock issued through employee stock purchase plan 3,714 — 8 — 8 Common stock issued, net of expenses 50,000 — 95 — 95 Common stock issued for vested restricted stock units 6,125 — — — — Balance, September 30, 2022 32,656,242 $ 36 $ 425,032 $ ( 407,859 ) $ 17,209 Three Months Ended September 30, 2021 Shares of Common Additional Accumulated Total Balance, June 30, 2021 23,147,552 $ 26 $ 361,925 $ ( 329,631 ) $ 32,320 Net loss — — — ( 605 ) ( 605 ) Stock-based compensation expense — — 588 — 588 Common stock issued through employee stock purchase plan 2,759 — 13 — 13 Common stock issued, net of expenses 733,937 1 5,300 — 5,301 Common stock issued for vested restricted stock units 1,322 — ( 3 ) — ( 3 ) Balance, September 30, 2021 23,885,570 $ 27 $ 367,823 $ ( 330,236 ) $ 37,614 Nine Months Ended September 30, 2022 Shares of Common Additional Accumulated Total Balance, December 31, 2021 28,705,334 $ 32 $ 400,705 $ ( 359,479 ) $ 41,258 Net loss — — — ( 48,380 ) ( 48,380 ) Stock-based compensation expense — — 3,232 — 3,232 Common stock issued through employee stock purchase plan 6,834 — 18 — 18 Common stock issued, net of expenses 3,895,943 4 21,006 — 21,010 Common stock issued for vested restricted stock units 48,131 — — — — Vested Loan Agreement warrants — — 71 — 71 Balance, September 30, 2022 32,656,242 $ 36 $ 425,032 $ ( 407,859 ) $ 17,209 Nine Months Ended September 30, 2021 Shares of Common Additional Accumulated Total Balance, December 31, 2020 19,663,698 $ 20 $ 349,351 $ ( 326,613 ) $ 22,758 Net loss — — — ( 3,623 ) ( 3,623 ) Stock-based compensation expense — — 1,528 — 1,528 Common stock issued through employee stock purchase plan 4,943 — 22 — 22 Common stock issued, net of expenses 3,250,739 6 8,707 — 8,713 Common stock issued for conversion of April 2020 Notes 959,080 1 7,452 — 7,453 Common stock issued for vested restricted stock units 7,110 — ( 3 ) — ( 3 ) Vested Loan Agreement warrants — — 766 — 766 Balance, September 30, 2021 23,885,570 $ 27 $ 367,823 $ ( 330,236 ) $ 37,614
Common Stock Reserved For Future Issuances	The Company had reserved shares of common stock for future issuance as follows: September 30, 2022 December 31, 2021 Outstanding stock options 2,125,002 1,542,126 Outstanding restricted stock units 990,015 133,834 Warrants to purchase common stock associated with March 2018 public offering – Series 2 798,810 798,810 Warrants to purchase common stock associated with December 2020 public offering - Series 2 6,800,000 6,800,000 Prefunded warrants to purchase common stock associated with December 2020 public offering 3,200,000 3,200,000 Warrants to purchase common stock associated with April 2022 Public Offering 15,000,000 — Prefunded warrants to purchase common stock associated with April 2022 Public Offering 11,666,667 — Warrants to purchase common stock associated with Loan Agreement 198,819 170,410 Warrant to purchase common stock associated with Danforth 50,000 50,000 For possible future issuance for the conversion of the March 2019 Notes 1,138,200 1,138,200 For possible future issuance under 2014 Plan (Note 10) 62,995 295,220 For possible future issuance under employee stock purchase plan — 3,893 For possible future issuance under 2015 Plan (Note 10) 128,250 235,000 Total common shares reserved for future issuance 42,158,758 14,367,493

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock Option Activity	The activity for the Company’s 2009 Stock Option Plan, 2014 Plan, and 2015 Plan, for the nine months ended September 30, 2022, is summarized as follows: Number of Weighted- Weighted- Aggregate Outstanding — December 31, 2021 1,542,126 $ 14.89 7.45 $ 42 Granted 664,000 $ 4.15 Forfeited/Cancelled ( 81,124 ) $ 7.42 Outstanding — September 30, 2022 2,125,002 $ 11.82 7.61 $ 49 Exercisable — September 30, 2022 1,052,080 $ 18.11 6.30 $ — Vested or expected to vest — September 30, 2022 2,125,002 $ 11.82 7.61 $ 49
Schedule of Restricted Stock Units ("RSU") Activity	Restricted stock unit (“RSU”) activity under the 2014 Plan and 2015 Plan for the nine months ended September 30, 2022, is summarized as follows: Number of Weighted Non-vested at December 31, 2021 133,834 $ 7.98 Granted 943,465 $ 5.35 Vested ( 48,131 ) $ 8.29 Forfeited ( 39,153 ) $ 6.28 Non-vested at September 30, 2022 990,015 $ 5.52
Stock-Based Compensation Expense Related to Stock Options	Stock-based compensation expense related to stock options is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Research and development $ 327 $ 174 $ 955 $ 436 Selling, general and administrative 710 414 2,104 1,092 Total $ 1,037 $ 588 $ 3,059 $ 1,528

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured on a Recurring Basis	The following table summarizes the conclusions reached as of September 30, 2022 and December 31, 2021 for financial instruments measured at fair value on a recurring basis (in thousands): Fair Value Hierarchy Classification Balance Quoted Significant Significant September 30, 2022 Cash $ ( 59 ) $ ( 59 ) — — Restricted cash 218 218 — — Money market funds 68,679 68,679 — — Total assets $ 68,838 $ 68,838 — — Warrant liabilities $ 27,730 — — $ 27,730 Derivative liability 238 — — 238 Total liabilities $ 27,968 — — $ 27,968 December 31, 2021 Cash $ 310 $ 310 — — Restricted cash 218 218 — — Money market funds 104,187 104,187 — — Total assets $ 104,715 $ 104,715 — — Warrant liabilities $ 18,062 — — $ 18,062 Derivative liability 1,358 — — 1,358 Total liabilities $ 19,420 — — $ 19,420
Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis	A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands): Warrant Liabilities Balance – December 31, 2021 $ 18,062 April 2022 Public Offering warrant issuance 24,704 Loan Agreement warrants ( 71 ) Gain adjustment to fair value ( 14,965 ) Balance – September 30, 2022 $ 27,730 Derivative Liability Balance – December 31, 2021 $ 1,358 Gain adjustment to fair value ( 1,120 ) Balance – September 30, 2022 $ 238

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Summary of Activity in Each of Product Revenue Provision and Allowance Categories	The following table summarizes activity in each of the Company’s product revenue provision and allowance categories as of September 30, 2022 (in thousands): Discounts and Chargebacks (1) Product Returns (2) Rebates and Incentives (3) Total Balance as of December 31, 2021 $ 249 $ 21 $ 1,110 $ 1,380 Provision related to current period revenue 1,124 38 2,998 4,160 Changes in estimate related to prior period revenue ( 31 ) — 55 24 Credit/payments ( 742 ) — ( 2,982 ) ( 3,724 ) Balance as of September 30, 2022 $ 600 $ 59 $ 1,181 $ 1,840 (1) Discounts and chargebacks include fees for wholesaler fees, prompt pay and other discounts, and chargebacks. Discounts and chargebacks are deducted from gross revenue at the time revenues are recognized and are included as a reduction in accounts receivable or as an accrued expense based on their nature on the Company’s unaudited condensed consolidated balance sheet. (2) Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Company’s unaudited condensed consolidated balance sheet. (3) Rebates and incentives include rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Company’s unaudited condensed consolidated balance sheets.

Description of Business and B_2

Description of Business and Basis of Preparation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Accumulated deficit	$ 407,859		$ 407,859		$ 359,479
Cash and cash equivalents and short-term investments	96,100		96,100
Income tax benefit	$ 0	$ 50	4,700	$ 3,088
New Jersey
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Income tax benefit			$ 4,700

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - Pre-funded Warrants - shares	Sep. 30, 2022	Apr. 22, 2022	Sep. 30, 2021
December 2020 Public Offering
Subsidiary Sale Of Stock [Line Items]
Number of outstanding warrants issued to purchase common stock (in shares)	3,200,000		3,200,000
April 2022 Public Offering
Subsidiary Sale Of Stock [Line Items]
Number of outstanding warrants issued to purchase common stock (in shares)	11,666,667	11,666,667

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Common Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Accounting Policies [Abstract]
Net loss	$ (29,584)	$ (605)	$ (48,380)	$ (3,623)
Dilutive effect of warrant liability	0	0	0	(15,719)
Dilutive effect of convertible debt	0	(988)	0	0
Net loss allocated to common shares	$ (29,584)	$ (1,593)	$ (48,380)	$ (19,342)
Weighted average common shares outstanding – basic	47,503,821	26,616,628	40,965,908	26,147,658
Dilutive effect of warrant liability	0	0	0	178,348
Dilutive effect of convertible debt	0	1,138,200	0	0
Weighted average common shares outstanding – diluted	47,503,821	27,754,828	40,965,908	26,326,006
Net loss per share – diluted	$ (0.62)	$ (0.06)	$ (1.18)	$ (0.73)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	27,100,846	20,473,931	27,100,846	15,172,265
Outstanding stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	2,125,002	1,643,506	2,125,002	1,643,506
Outstanding restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	990,015	149,134	990,015	149,134
Warrants to purchase common stock associated with December 2019 Public Offering | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)		4,472,205		4,472,205
December 2020 Public Offering Series 1
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)		6,439,866
December 2020 Public Offering Series 2 | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	6,800,000	6,800,000	6,800,000	6,800,000
April 2022 Public Offering | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	15,000,000	0	15,000,000	0
March 2018 Public Offering Series 2 | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	798,810	798,810	798,810	798,810
Warrants to purchase common stock associated with Loan Agreement | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	198,819	170,410	198,819	170,410
Common stock associated with March 2019 Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	1,138,200	0	1,138,200	1,138,200
Warrants to purchase common stock associated with Danforth | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	50,000	0	50,000	0

Short-term investments - Summar

Short-term investments - Summary Of Short-term Investments (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	$ 27,470
Unrealized Gains	0
Unrealized Losses	(164)
Fair Value	27,306
U.S. government securities
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	27,470
Unrealized Gains	0
Unrealized Losses	(164)
Fair Value	$ 27,306

Short-term Investments - Additi

Short-term Investments - Additional Information (Details) $ in Millions	Sep. 30, 2022 USD ($)
Investments, Debt and Equity Securities [Abstract]
Held-to-maturity investments	$ 27.5

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid research and development services	$ 857	$ 247
Prepaid insurance	543	505
Other prepaid expenses	2,737	2,813
Other current assets	4	4
Total prepaid expenses and other current assets	$ 4,141	$ 3,569

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 5,331	$ 5,162
Work in process	0	3
Finished goods	56	127
Total inventory	$ 5,387	$ 5,292

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Other Assets
Inventory [Line Items]
Raw material classified as long term	$ 4.6	$ 4.8

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued research and development expenses	$ 783	$ 1,498
Accrued employee bonus compensation	1,821	2,012
Other accrued expenses	2,580	1,352
Accrued co-pay rebates	672	836
Total accrued expenses	$ 5,856	$ 5,698

Borrowings - Additional Informa

Borrowings - Additional Information (Detail)				1 Months Ended	3 Months Ended		9 Months Ended
	May 13, 2021 USD ($) Tranche	Apr. 09, 2020 USD ($)	Mar. 07, 2019 USD ($)	Jan. 31, 2021 USD ($) shares	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)
Debt Instrument [Line Items]
Face amount					$ 36,383,000		$ 36,383,000
Loss on extinguishment of debt					0	$ 0	0	$ 2,725,000
Net carrying amount of convertible debt and derivative liability					11,032,000		11,032,000			$ 11,607,000
Gain (loss) on fair value adjustment of derivative liability					(42,000)	1,400,000		1,900,000
Amortization of debt issuance costs and discount					396,000	413,000	1,194,000	937,000
Deferred offering costs					73,000		73,000			150,000
Repayment of deferred fee, 2023					0		0
Repayment of deferred fee, 2024					23,684,000		23,684,000
Repayment of deferred fee, 2025					11,316,000		11,316,000
Other Liabilities
Debt Instrument [Line Items]
Deferred offering costs					$ 4,900,000		$ 4,900,000			3,300,000
Interest rate, deferred fees					12.75%		12.75%
Percentage of repayment of deferred fee, 2023							15%
Percentage of repayment of deferred fee, 2024							50%
Percentage of repayment of deferred fee, 2025					35%		35%
Repayment of deferred fee, 2023					$ 1,000,000		$ 1,000,000
Repayment of deferred fee, 2024					2,600,000		2,600,000
Repayment of deferred fee, 2025					2,000,000		2,000,000
SVB
Debt Instrument [Line Items]
Minimum outstanding term loan principal percentage for financial covenant waived	50%
Loan and Security Agreement
Debt Instrument [Line Items]
Fair value of loan payable					$ 33,700,000		$ 33,700,000			$ 29,200,000
Loan and Security Agreement | Level 3 Inputs | Secured Spread
Debt Instrument [Line Items]
Debt instrument, measurement input					10.16		10.16			9.30
Loan and Security Agreement | Level 3 Inputs | Risk Free Rate
Debt Instrument [Line Items]
Debt instrument, measurement input					4.23		4.23			1
Loan and Security Agreement | Level 3 Inputs | Secured Yield
Debt Instrument [Line Items]
Debt instrument, measurement input					14.39		14.39			10.30
Term Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Notes maturity date	Mar. 03, 2025
Basis spread on variable rate (as a percent)	9.05%
Debt instrument maturity date subject to occurrence of certain conditions	May 01, 2025
Term Loan | Loan and Security Agreement | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)	5.80%
Term Loan | Loan and Security Agreement | Hercules Capital Inc. and Silicon Valley Bank
Debt Instrument [Line Items]
Face amount	$ 60,000,000
Number of available tranches | Tranche	4
Initial Tranche of Term Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Additional borrowing amount available	$ 20,000,000
Second Tranche of Term Loan
Debt Instrument [Line Items]
Face amount											$ 10,000,000
Second Tranche of Term Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Additional borrowing amount available	10,000,000
Third Tranche of Term Loan
Debt Instrument [Line Items]
Face amount									$ 5,000,000
Third Tranche of Term Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Additional borrowing amount available	5,000,000
Fourth Tranche of Term Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Additional borrowing amount available	25,000,000
Increment debt amount	$ 5,000,000
April 2020 Note Purchase Agreement
Debt Instrument [Line Items]
Face amount		$ 10,000,000
Date of issuance and sale of notes		Apr. 09, 2020
Proceeds from debt, net of issuance costs		$ 9,500,000
Payment of debt issuance costs		$ 500,000
Conversion of convertible note, amount				$ 6,000,000
Conversion of convertible note exchanged for shares | shares				959,080
Loss on extinguishment of debt				$ 2,700,000
Net carrying amount of convertible debt and derivative liability				4,800,000
Fair value of the consideration issued				$ 7,500,000
Senior Convertible Note Purchase Agreement
Debt Instrument [Line Items]
Face amount			$ 16,000,000
Notes maturity date			Mar. 15, 2025
Date of issuance and sale of notes			Mar. 07, 2019
Proceeds from debt, net of issuance costs			$ 14,700,000
Payment of debt issuance costs			$ 1,300,000
Senior convertible notes					$ 10,800,000		$ 10,800,000			$ 10,200,000
Unamortized debt issuance cost					300,000		300,000
Bifurcated embedded conversion option derivative liability					200,000		200,000			1,400,000
Derivative, fair value					7,000,000		7,000,000
Gain (loss) on fair value adjustment of derivative liability							1,100,000
Amortization of debt issuance costs and discount					200,000	$ 200,000	500,000	$ 700,000
Fair value of convertible debt and derivative liability					$ 10,600,000		$ 10,600,000			$ 12,300,000
Interest rate			6%
Payment terms							The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased.

Borrowings - Schedule of Future

Borrowings - Schedule of Future Principal Debt Payments On Currently Outstanding Loan Payable (Detail) $ in Thousands	Sep. 30, 2022 USD ($)
Debt Disclosure [Abstract]
2022	$ 0
2023	0
2024	23,684
2025	11,316
Total principal payments	35,000
Final fee due at maturity	1,383
Total principal and final fee payment	36,383
Unamortized discount and debt issuance costs	(2,221)
Less current portion	0
Loan payable, long term	$ 34,162

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)		3 Months Ended		9 Months Ended
	Mar. 01, 2018 USD ($) ft²	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Commitment And Contingencies [Line Items]
Long-term lease agreement, area of office space | ft²	19,275
Lease term	11 years
Total lease payments	$ 7,300,000	$ 118,000	$ 116,000	$ 350,000	$ 343,000
Lessee, operating lease, existence of option to extend	true
Renewal term	5 years
Renewal term, description				The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which was reduced by fifty-five thousand dollars on the first anniversary of the commencement date. The security deposit will continue to be reduced by fifty-five thousand dollars every two years on the commencement date anniversary for eight years.
Security deposit in the form of a standby letter of credit	$ 300,000
Decrease in security deposit	$ 55,000
Maximum
Commitment And Contingencies [Line Items]
Milestone payments from the Company				$ 19,000,000

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Unaudited Condensed Consolidated Financial Statements for Lease (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Mar. 01, 2018	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost		$ 166	$ 166	$ 498	$ 498
Variable lease cost		8	9	13	18
Total operating lease expense		174	175	511	516
Total lease payments	$ 7,300	$ 118	$ 116	$ 350	$ 343
Remaining Lease term (years)		6 years 10 months 2 days		6 years 10 months 2 days		7 years 7 months 2 days
Discount rate		15%		15%		15%

Commitments and Contingencies_3

Commitments and Contingencies - Future Minimum Lease Payments (Detail) $ in Thousands	Sep. 30, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 177
2023	715
2024	730
2025	744
2026	759
Thereafter	2,030
Total	$ 5,155

Commitments and Contingencies_4

Commitments and Contingencies - Presentation of Operating Lease Liability (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Present value of future minimum lease payments	$ 3,267
Operating lease liability, current portion	269	$ 70
Operating lease liability, long-term portion	2,998	$ 3,204
Total operating lease liability	3,267
Difference between future minimum lease payments and discounted cash flows	$ 1,888

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)			1 Months Ended	3 Months Ended			9 Months Ended
	Apr. 22, 2022 USD ($) $ / shares shares	Apr. 10, 2020 USD ($)	Jun. 30, 2021 USD ($) shares	Sep. 30, 2022 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) shares	Sep. 30, 2021 USD ($) shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) shares	Sep. 29, 2022 shares	Jun. 30, 2022 shares	Dec. 31, 2021 USD ($) $ / shares shares	May 31, 2021 $ / shares shares	Dec. 31, 2020 shares
Schedule Of Capitalization Equity [Line Items]
Common stock, par value (in dollars per share) | $ / shares				$ 0.001			$ 0.001				$ 0.001
Common stock, shares authorized (in shares)				150,000,000			150,000,000		100,000,000		100,000,000
Common stock, shares issued (in shares)				32,656,242			32,656,242				28,705,334
Common stock, shares outstanding (in shares)				32,656,242			32,656,242				28,705,334
Proceeds from common stock issued | $							$ 47,248,000	$ 8,027,000
Warrant liabilities fair value adjustment | $				$ 6,497,000		$ (18,810,000)	(13,215,000)	(35,378,000)
Warrant liabilities | $				27,700,000			27,700,000				$ 18,100,000
Face amount | $				$ 36,383,000			36,383,000
Reclass of warrant liability to additional paid in capital | $							$ 71,000	$ 298,000
Second Tranche of Term Loan
Schedule Of Capitalization Equity [Line Items]
Face amount | $			$ 10,000,000
Reclass of warrant liability to additional paid in capital | $			$ 300,000
Third Tranche of Term Loan
Schedule Of Capitalization Equity [Line Items]
Face amount | $					$ 5,000,000
Reclass of warrant liability to additional paid in capital | $					$ 100,000
Loan and Security Agreement | Hercules Capital Inc. and Silicon Valley Bank
Schedule Of Capitalization Equity [Line Items]
Common stock, par value (in dollars per share) | $ / shares												$ 0.001
Number of warrants issued to purchase common stock (in shares)												113,607
Multiplier value by aggregate amount of the term loan advances divided by exercise price of warrants to calculate number of shares for purchase												0.04
Loan and Security Agreement | Second Tranche of Term Loan | Hercules Capital Inc. and Silicon Valley Bank
Schedule Of Capitalization Equity [Line Items]
Common stock, shares issued (in shares)			56,803
Loan and Security Agreement | Third Tranche of Term Loan | Hercules Capital Inc. and Silicon Valley Bank
Schedule Of Capitalization Equity [Line Items]
Common stock, shares issued (in shares)					28,409
Cantor Fitzgerald & Co. and Ladenburg Thalmann & Co. Inc. | Sales Agreement
Schedule Of Capitalization Equity [Line Items]
Common stock issued, net of expenses (in shares)				0		1,900,000	137,610	430,605
Proceeds from common stock issued | $				$ 0		$ 333,937	$ 700,000	$ 2,500,000
Aspire Capital | Common Stock Purchase Agreement
Schedule Of Capitalization Equity [Line Items]
Common stock issued, net of expenses (in shares)				50,000		400,000	425,000	400,000
Proceeds from common stock issued | $				$ 100,000		$ 2,600,000	$ 1,600,000	$ 2,600,000
Maximum | Aspire Capital | Common Stock Purchase Agreement
Schedule Of Capitalization Equity [Line Items]
Sale of common stock at sole discretion | $		$ 20,000,000
Common Stock
Schedule Of Capitalization Equity [Line Items]
Common stock, shares outstanding (in shares)			23,147,552	32,656,242		23,885,570	32,656,242	23,885,570		32,596,403	28,705,334		19,663,698
Common stock issued, net of expenses (in shares)				50,000		733,937	3,895,943	3,250,739
April 2022 Public Offering
Schedule Of Capitalization Equity [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.001
Common stock issued, net of expenses (in shares)	3,333,333
Proceeds from common stock issued | $	$ 41,800,000
Warrant liabilities fair value adjustment | $							$ 1,700,000
April 2022 Public Offering | Series 2 Warrant
Schedule Of Capitalization Equity [Line Items]
Exercise price of warrants (in dollars per share) | $ / shares	$ 3.45
Warrant term	7 years
April 2022 Public Offering | Series 2 Warrant | Maximum
Schedule Of Capitalization Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)	15,000,000
Number of shares received per warrant (in shares)	15,000,000
April 2022 Public Offering | Series 1 Warrant
Schedule Of Capitalization Equity [Line Items]
Exercise price of warrants (in dollars per share) | $ / shares	$ 0.001
April 2022 Public Offering | Series 1 Warrant | Maximum
Schedule Of Capitalization Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)	11,666,667
April 2022 Public Offering | Common Stock
Schedule Of Capitalization Equity [Line Items]
Public offering price | $ / shares	$ 3
April 2022 Public Offering | Pre-funded Warrants
Schedule Of Capitalization Equity [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.001
Number of warrants issued to purchase common stock (in shares)	11,666,667			11,666,667			11,666,667
Public offering price | $ / shares	$ 2.999

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Common Stock Shares Activity (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance	$ 45,480,000	$ 32,320,000	$ 41,258,000	$ 22,758,000
Beginning balance (in shares)			28,705,334
Net loss	(29,584,000)	(605,000)	$ (48,380,000)	(3,623,000)
Stock-based compensation expense	1,210,000	588,000	323,200	1,528,000
Common stock issued through employee stock purchase plan	8,000	13,000	18,000	22,000
Common stock issued, net of expenses	95,000	5,301,000	21,010,000	8,713,000
Common stock issued for vested restricted stock units	0	(3,000)	0	(3,000)
Vested Loan Agreement warrants			71,000	766,000
Ending balance	$ 17,209,000	37,614,000	$ 17,209,000	37,614,000
Ending balance (in shares)	32,656,242		32,656,242
April 2020 Notes
Common Stock Outstanding Roll Forward [Roll Forward]
Common stock issued for conversion of Notes				7,453,000
Common Stock
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance	$ 36,000	$ 26,000	$ 32,000	$ 20,000
Beginning balance (in shares)	32,596,403	23,147,552	28,705,334	19,663,698
Net loss	$ 0	$ 0	$ 0	$ 0
Stock-based compensation expense		0		0
Common stock issued through employee stock purchase plan		$ 0		$ 0
Common stock issued through employee stock purchase (in shares)	3,714	2,759	6,834	4,943
Common stock issued, net of expenses	$ 0	$ 1,000	$ 4,000	$ 6,000
Common stock issued, net of expenses (in shares)	50,000	733,937	3,895,943	3,250,739
Common stock issued for vested restricted stock units	$ 0	$ 0	$ 0	$ 0
Common stock issued for vested restricted stock units (in shares)	6,125	1,322	48,131	7,110
Vested Loan Agreement warrants			$ 0	$ 0
Ending balance	$ 36,000	$ 27,000	$ 36,000	$ 27,000
Ending balance (in shares)	32,656,242	23,885,570	32,656,242	23,885,570
Common Stock | April 2020 Notes
Common Stock Outstanding Roll Forward [Roll Forward]
Common stock issued for conversion of Notes				$ 1,000
Common stock issued for conversion of Notes (in shares)				959,080
Additional Paid-in Capital
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance	$ 423,719,000	$ 361,925,000	$ 400,705,000	$ 349,351,000
Net loss	0	0	0	0
Stock-based compensation expense	1,210,000	588,000	3,232,000	1,528,000
Common stock issued through employee stock purchase plan	8,000	13,000	18,000	22,000
Common stock issued, net of expenses	95,000	5,300,000	21,006,000	8,707,000
Common stock issued for vested restricted stock units	0	(3,000)	0	(3,000)
Vested Loan Agreement warrants			71,000	766,000
Ending balance	425,032,000	367,823,000	425,032,000	367,823,000
Additional Paid-in Capital | April 2020 Notes
Common Stock Outstanding Roll Forward [Roll Forward]
Common stock issued for conversion of Notes				7,452,000
Accumulated Deficit
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance	(378,275,000)	(329,631,000)	(359,479,000)	(326,613,000)
Net loss	(29,584,000)	(605,000)	(48,380,000)	(3,623,000)
Stock-based compensation expense		0		0
Common stock issued through employee stock purchase plan		0		0
Common stock issued, net of expenses	0	0	0	0
Common stock issued for vested restricted stock units	0	0	0	0
Vested Loan Agreement warrants			0	0
Ending balance	$ (407,859,000)	$ (330,236,000)	$ (407,859,000)	(330,236,000)
Accumulated Deficit | April 2020 Notes
Common Stock Outstanding Roll Forward [Roll Forward]
Common stock issued for conversion of Notes				$ 0

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) - shares	Sep. 30, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Common shares reserved for future issuance	42,158,758	14,367,493
Stock options
Class of Stock [Line Items]
Common shares reserved for future issuance	2,125,002	1,542,126
Restricted Stock Units
Class of Stock [Line Items]
Common shares reserved for future issuance	990,015	133,834
Warrant | March 2018 Public Offering
Class of Stock [Line Items]
Common shares reserved for future issuance	798,810	798,810
Warrant | December 2020 Public Offering Series 2
Class of Stock [Line Items]
Common shares reserved for future issuance	6,800,000	6,800,000
Warrant | Prefunded Warrants to Purchase Common Stock Associated with December 2020 Public Offering
Class of Stock [Line Items]
Common shares reserved for future issuance	3,200,000	3,200,000
Warrant | Warrants to Purchase Common Stock Associated With April 2022 Public Offering
Class of Stock [Line Items]
Common shares reserved for future issuance	15,000,000	0
Warrant | April 2022 Public Offering
Class of Stock [Line Items]
Common shares reserved for future issuance	11,666,667	0
Warrant | Warrant to purchase common stock associated with Danforth
Class of Stock [Line Items]
Common shares reserved for future issuance	50,000	50,000
Warrant | Warrants to purchase common stock associated with Loan Agreement
Class of Stock [Line Items]
Common shares reserved for future issuance	198,819	170,410
March 2019 Notes
Class of Stock [Line Items]
Common shares reserved for future issuance	1,138,200	1,138,200
2014 Employee Stock Purchase Plan
Class of Stock [Line Items]
Common shares reserved for future issuance	0	3,893
2014 Plan
Class of Stock [Line Items]
Common shares reserved for future issuance	62,995	295,220
2015 Plan
Class of Stock [Line Items]
Common shares reserved for future issuance	128,250	235,000

Stock-based Compensation - 2014

Stock-based Compensation - 2014 Equity Incentive Plan (Detail) - 2014 Equity Incentive Plan - shares	Jan. 01, 2022	Jan. 01, 2021	Sep. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of additional shares authorized	1,148,213	786,547
Possible future issuance under equity compensation plan (in shares)			62,995

Stock-based Compensation - 2015

Stock-based Compensation - 2015 Inducement Award Plan (Detail) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option to purchase (shares)	664,000
2015 Inducement Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Possible future issuance under equity compensation plan (in shares)	128,250
Option to purchase (shares)	109,000	182,600

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Number of Shares
Beginning balance - Outstanding (shares)	1,542,126
Granted (shares)	664,000
Forfeited/Cancelled (shares)	(81,124)
Ending balance - Outstanding (shares)	2,125,002	1,542,126
Exercisable (shares)	1,052,080
Vested or expected to vest (shares)	2,125,002
Weighted- Average Exercise Price
Beginning balance - Outstanding (in dollars per share)	$ 14.89
Granted (in dollars per share)	4.15
Forfeited/Cancelled (in dollars per share)	7.42
Ending balance - Outstanding (in dollars per share)	11.82	$ 14.89
Exercisable (in dollars per share)	18.11
Vested or expected to vest (in dollars per share)	$ 11.82
Weighted- Average Remaining Contractual Life (in years)
Balance - Outstanding	7 years 7 months 9 days	7 years 5 months 12 days
Exercisable	6 years 3 months 18 days
Vested or expected to vest	7 years 7 months 9 days
Aggregate Intrinsic Value ($000)
Balance - Outstanding	$ 49	$ 42
Exercisable	0
Vested and expected to vest	$ 49

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Restricted Stock Units ("RSU") Activity (Detail) - Outstanding restricted stock units	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Number of Shares
Beginning balance - Outstanding (shares) | shares	133,834
Options granted in period (shares) | shares	943,465
Vested (shares) | shares	(48,131)
Forfeited (shares) | shares	(39,153)
Ending balance - Outstanding (shares) | shares	990,015
Weighted Average Grant Date Fair Value Per Share
Beginning balance - Outstanding (in dollars per share) | $ / shares	$ 7.98
Granted (in dollars per share) | $ / shares	5.35
Vested (in dollars per share) | $ / shares	8.29
Forfeited (in dollars per share) | $ / shares	6.28
Ending balance - Outstanding (in dollars per share) | $ / shares	$ 5.52
Vesting percentage	25%
Vesting period of options	4 years

Stock-based Compensation - Comp

Stock-based Compensation - Compensation Cost (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Stock-based compensation expense	$ 1,037,000	$ 588,000	$ 3,059,000	$ 1,528,000
Tax benefit from compensation expense	$ 0	$ 0	$ 0	$ 0

Stock-based Compensation - St_2

Stock-based Compensation - Stock-Based Compensation Expense Related to Stock Options (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 1,037	$ 588	$ 3,059	$ 1,528
Research and development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	327	174	955	436
Selling, general and administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 710	$ 414	$ 2,104	$ 1,092

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash	$ (59)	$ 310
Fair value of financial assets	68,838	104,715
Fair value of financial liabilities	27,968	19,420
Warrant liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	27,730	18,062
Derivative liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	238	1,358
Restricted cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	218	218
Money market funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	68,679	104,187
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash	(59)	310
Fair value of financial assets	68,838	104,715
Fair value of financial liabilities	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Derivative liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Restricted cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	218	218
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	68,679	104,187
Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash	0	0
Fair value of financial assets	0	0
Fair value of financial liabilities	0	0
Significant Other Observable Inputs (Level 2) | Warrant liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	0	0
Significant Other Observable Inputs (Level 2) | Derivative liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	0	0
Significant Other Observable Inputs (Level 2) | Restricted cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Significant Other Observable Inputs (Level 2) | Money market funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Significant Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash	0	0
Fair value of financial assets	0	0
Fair value of financial liabilities	27,968	19,420
Significant Unobservable Inputs (Level 3) | Warrant liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	27,730	18,062
Significant Unobservable Inputs (Level 3) | Derivative liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	238	1,358
Significant Unobservable Inputs (Level 3) | Restricted cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Significant Unobservable Inputs (Level 3) | Money market funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	$ 0	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - Significant Unobservable Inputs (Level 3)	Sep. 30, 2022
Stock Price Volatility
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Derivative liabilities, unobservable inputs rate	65.7
Stock Price Volatility | Minimum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liabilities, stock price volatility rate	81.7
Stock Price Volatility | Maximum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liabilities, stock price volatility rate	84.8
Stock Price Volatility | Weighted Average
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liabilities, stock price volatility rate	84.7
Market Credit Spread
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Derivative liabilities, unobservable inputs rate	1,544
Estimated Yield
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Derivative liabilities, unobservable inputs rate	19.7

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Warrant
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 18,062
April 2022 Public Offering warrant issuance	24,704
Loan Agreement warrants	(71)
Gain (loss) adjustment to fair value	(14,965)
Ending balance	27,730
Derivative liabilities
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	1,358
Gain (loss) adjustment to fair value	(1,120)
Ending balance	$ 238

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation Of Revenue [Line Items]
Revenue	$ 1,557	$ 516	$ 3,567	$ 12,566
Exclusive License And Collaboration Agreement
Disaggregation Of Revenue [Line Items]
Transaction Price				12,100
Fixed upfront cash payment				10,000
Amount related to withholding tax obligations				1,100
Sales Revenue Net | Customer Concentration Risk | Wholesaler One
Disaggregation Of Revenue [Line Items]
Percentage of gross revenue			45%
Sales Revenue Net | Customer Concentration Risk | Wholesaler Two
Disaggregation Of Revenue [Line Items]
Percentage of gross revenue			29%
Sales Revenue Net | Customer Concentration Risk | Wholesaler Three
Disaggregation Of Revenue [Line Items]
Percentage of gross revenue			20%
Product Revenue, Net
Disaggregation Of Revenue [Line Items]
Revenue	$ 1,557	$ 516	$ 3,567	$ 516

Revenue - Summary of Activity i

Revenue - Summary of Activity in Each of Product Revenue Provision and Allowance Categories (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Disaggregation Of Revenue [Line Items]
Balance	$ 1,380
Provision related to current period revenue	4,160
Changes in estimate related to prior period revenue	24
Credit/payments	(3,724)
Balance	1,840
Discounts and Chargebacks
Disaggregation Of Revenue [Line Items]
Balance	249
Provision related to current period revenue	1,124
Changes in estimate related to prior period revenue	(31)
Credit/payments	(742)
Balance	600
Product Returns
Disaggregation Of Revenue [Line Items]
Balance	21
Provision related to current period revenue	38
Changes in estimate related to prior period revenue	0
Credit/payments	0
Balance	59
Rebates and Incentives
Disaggregation Of Revenue [Line Items]
Balance	1,110
Provision related to current period revenue	2,998
Changes in estimate related to prior period revenue	55
Credit/payments	(2,982)
Balance	$ 1,181